Sep 7, 2026 · 54 min
How IM8 turned product conviction into rapid scale
How we scaled to $100M in under a year (ft. IM8 co-founder Danny Yeung)
The conversation examines whether exceptional products, disciplined acquisition, and operational realism can turn a crowded supplement category into a global business.
- 1IM8 paired a broad daily formula with scientific credibility, premium branding, and recurring subscriptions to differentiate in a crowded market.
- 2Its growth engine combines relentless creative testing, creator and affiliate partnerships, and offline events designed to build trust.
- 3Danny Yeung’s earlier ventures taught him to balance founder conviction with evidence, logistics, and the realities of scaling demand.
Don't miss
Danny explains how hundreds of offline events let customers meet scientists, formulators, and ambassadors, turning an online supplement brand into a more credible experience.
The brief
Danny Yeung traces IM8’s rise from a supplement concept to a $200 million annual run rate, then links that growth to lessons from earlier businesses.
IM8’s formula, taste, bold packaging, scientific advisory board, and subscription model were designed to make a crowded category feel more credible and convenient.
The growth machine runs on thousands of live ads, hundreds of creators tested weekly, ambassadors, affiliates, and offline events that make the brand tangible.
Expansion into China exposes the limits of simply exporting a U.S. direct-to-consumer playbook: pricing, education, branding, teams, and operations must change.
Yeung’s career—from teenage telemarketer to COVID-testing operator—frames the central lesson: conviction starts the company, but execution determines whether it survives.